Tsumura & Co stock (JP3429000008): earnings update and herbal medicine outlook

Japanese Kampo medicine specialist Tsumura & Co has reported higher profits for the latest fiscal year and issued guidance for the year ahead, offering investors fresh insight into demand trends for traditional herbal remedies and related prescription products.

Tsumura & Co, a leading Japanese provider of Kampo traditional herbal medicines, recently reported its financial results for the fiscal year ended March 31, 2025, alongside guidance for the current year, giving investors an updated view on revenue growth, profitability and demand for its prescription-based herbal formulations, according to the company’s earnings materials published on May 13, 2025 and May 14, 2025 on its investor relations website and related Tokyo Stock Exchange filings (Tsumura IR as of 05/14/2025 and JPX as of 05/14/2025).

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Tsumura
• Sector/industry: Pharmaceuticals / traditional herbal medicine
• Headquarters/country: Tokyo, Japan
• Core markets: Japan and selected Asian markets
• Key revenue drivers: Prescription Kampo formulations supplied to medical institutions and pharmacies
• Home exchange/listing venue: Tokyo Stock Exchange (ticker 4540)
• Trading currency: Japanese yen (JPY)

Tsumura & Co: core business model

Tsumura & Co focuses on the research, manufacture and sale of Kampo medicines, which are standardized traditional Japanese herbal formulations used alongside conventional pharmaceuticals in clinical practice. The company’s products are primarily prescribed by physicians and dispensed through hospitals and pharmacies, integrating traditional therapy into Japan’s modern healthcare system, according to its corporate profile and company history materials published on its website on March 31, 2025 (Tsumura corporate outline as of 03/31/2025).

Within this model, Tsumura operates a vertically integrated supply chain covering cultivation, procurement and quality control of herbal ingredients, as well as formulation development and manufacturing. The company emphasizes standardized dosing and evidence-based usage for Kampo products, aiming to meet pharmaceutical-level quality and regulatory standards for prescription medicines in Japan. This approach differentiates its offerings from over-the-counter supplements and focuses on physician-led treatment. The reliance on prescriptions also ties demand closely to reimbursement rules under Japan’s public health insurance framework.

Besides its core Kampo prescription line, Tsumura engages in related businesses such as crude drug preparations and certain health-related products, but these form a smaller part of revenue compared with the main prescription Kampo portfolio. The company also invests in clinical research to further validate Kampo formulations in areas such as gastroenterology, gynecology and oncology supportive care, which can support broader physician adoption over time, according to R&D and product pipeline documentation published alongside the fiscal 2024 and fiscal 2025 results on May 14, 2025 (Tsumura annual report as of 05/14/2025).

Main revenue and product drivers for Tsumura & Co

The bulk of Tsumura’s revenue comes from its Kampo prescription products sold to hospitals and clinics in Japan, where the healthcare system allows Kampo formulations to be prescribed and reimbursed under national insurance for defined indications. This structure supports recurring demand, as prescriptions are often written for chronic or recurrent conditions. Sales volumes therefore depend on both overall patient visits and the extent to which physicians choose Kampo therapies as part of treatment regimens, according to product sales breakdowns disclosed in the company’s financial statements for the year ended March 31, 2025, released on May 14, 2025 (Tsumura financial results as of 05/14/2025).

Key revenue drivers include Kampo remedies targeting gastrointestinal disorders, menopausal and gynecological symptoms, cold-like illnesses, fatigue and circulation issues, where the company has several well-established formulations. In those segments, Tsumura’s market share and prescribing habits by physicians play an important role. The company also benefits from demographic trends in Japan, where an aging population contributes to sustained demand for chronic disease management and supportive therapies. However, periodic revisions to reimbursement prices for Kampo medicines by Japanese authorities can pressure unit prices and margins, as indicated in the company’s discussion of risk factors and business environment in the annual securities report published in late June 2025 (Tsumura annual securities report as of 06/28/2025).

Outside Japan, Tsumura has been developing overseas business, including supplying herbal ingredients and exploring partnerships in Asian markets where traditional medicine usage is common. While international sales remain smaller relative to domestic revenue, these activities provide optionality for long-term growth if regulatory systems and reimbursement frameworks in other countries expand to recognize and support Kampo-based therapies. The company’s overseas efforts also include collaboration on raw material cultivation and quality assurance, which can support supply stability and potentially diversify sourcing risks, according to strategy explanations in the integrated report published on August 30, 2025, covering the fiscal year ended March 31, 2025 (Tsumura integrated report as of 08/30/2025).

Conclusion

Tsumura & Co offers investors exposure to Japan’s Kampo medicine market, which blends traditional herbal formulations with modern prescription-based healthcare. The company’s latest fiscal year results for the period ended March 31, 2025, released in mid-May 2025, showed continued revenue and profit generation from its core Kampo portfolio and included guidance for the new fiscal year, giving the market better visibility on expected trends in sales volumes, price revisions and cost structures. For US investors, the stock represents an example of a specialized Japanese pharmaceutical business whose performance is tied not only to demographic trends and clinical adoption, but also to local reimbursement policy and foreign exchange movements when translating yen-denominated returns into US dollars. As with all equities, potential investors typically weigh these factors, along with broader Japanese equity market conditions, before evaluating whether the shares fit their risk tolerance and portfolio objectives.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.